Eravacycline,  the First and Unique Fluorocycline Antibacterial Agent

Mohammad Saydur Rahman; Sharmila Sultana Shathi; G M Al Amin; Fatema Akhter; Md Ferdaus Azam; Sonia Akter; Md Ariful Islam; A K Azad; Young-Sang Koh

doi:10.4167/jbv.2024.54.1.001

All Issue

2024 Vol.54, Issue 1 Next Page

Review Article

Eravacycline, the First and Unique Fluorocycline Antibacterial Agent

31 March 2024. pp. 1-11

PDF XML

Abstract

Fluorocycline has been approved for the treatment of complicated intra-abdominal infections (cIAIs) caused by gram-positive and gram-negative bacteria in nosocomial infections. Especially, eravacycline is a unique synthetic fluorocycline antibacterial agent that belongs to the tetracycline class. It acts against multidrug- resistant microorganisms such as carbapenem-resistant Enterobacteriaceae and extended-spectrum β-lactamase-generating bacteria. Representing the most advanced class of tetracyclines, eravacycline demonstrates broad-spectrum antibacterial activity against aerobic and anaerobic microorganisms. It can be an excellent replacement for carbapenem in treating β-lactam-induced allergic patients owing to its activity against extended-spectrum β-lactamase-producing strains. Furthermore, it exhibits efficacy against methicillin-resistant Staphylococcus aureus and many atypical pathogens for which carbapenems have shown a dispiriting effect. In vitro, eravacycline was effective against a broad spectrum of clinically related gram-positive and gram-negative bacteria that express acquired resistance mechanisms toward the standard tetracycline classes. The intravenous dosage form of eravacycline has been used in many countries, including the USA and the EU, for treating cIAIs with severe complications in hospitalized patients (aged ≥ 18). Its greater efficacy and superior tolerability index compared with other tetracycline- class drugs (such as tigecycline) make it the best option for treating cIAIs. Its broad-spectrum activity against the most common clinically related pathogens makes it unique compared with its other analogs. Thus, it has become a practical choice as an empirical therapy for the treatment of pathogens. In this review, we address the possibility of employing eravacycline to treat bacterial infections, focusing on its chemistry, mode of action, pharmacokinetics, treatment indications, adverse effects, and safety profiles.

Keywords

Eravacycline

Tetracycline

Extended-spectrum β-lactamase

Complicated intra-abdominal infections

Tigecycline

Carbapenem

References

Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol 2010;1:134. 10.3389/fmicb.2010.0013421687759PMC3109405

Rahman MS, Koh YS. Omadacycline, a magic antibiotics for bacterial infections. J Bacteriol Virol 2018;48:109-12. 10.4167/jbv.2018.48.3.109

Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci 2011;1241:17-32. 10.1111/j.1749-6632.2011.06354.x22191524

Bassett EJ, Keith MS, Armelagos GJ, Martin DL, Villanueva AR. Tetracycline-labeled human bone from ancient Sudanese Nubia (A.D. 350). Science 1980;209:1532-4. 10.1126/science.70016237001623

Heaney M, Mahoney MV, Gallagher JC. Eravacycline: the tetracyclines strike back. Ann Pharmacother 2019;53: 1124-35. 10.1177/106002801985017331081341

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 2016;76:567-88. 10.1007/s40265-016-0545-826863149

Terreni M, Taccani M, Pregnolato M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. Molecules 2021;26:2671. 10.3390/molecules2609267134063264PMC8125338

Monogue ML, Thabit AK, Hamada Y, Nicolau DP. Antibacterial efficacy of eravacycline in vivo against gram-positive and gram-negative organisms. Antimicrob Agents Chemother 2016;60:5001-5. 10.1128/AAC.00366-1627353265PMC4958151

Rahman MS, Koh YS. A novel antibiotic agent, cefiderocol, for multidrug-resistant Gram-negative bacteria. J Bacteriol Virol 2020;50:218-26. 10.4167/jbv.2020.50.4.218

Rahman MS, Al Amin GM, Anwar SM, Azam MF, Akhter F, Islam MR, et al. Plazomicin-a new aminoglycoside-for treating complicated urinary tract infections. J Bacteriol Virol 2023;53:1-10. 10.4167/jbv.2023.53.1.001

Grossman TH, Murphy TM, Slee AM, Lofland D, Sutcliffe JA. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother 2015;59:2567-71. 10.1128/AAC.04354-1425691636PMC4394802

Montravers P, Zappella N, Tran-Dinh A. Eravacycline for the treatment of complicated intra-abdominal infections. Expert Rev Anti Infect Ther 2019;17:851-63. 10.1080/14787210.2019.168197531622119

Zhang Y, Lin X, Bush K. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot 2016;69:600-4. 10.1038/ja.2016.7327353166

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model. Antimicrob Agents Chemother 2017;61:e00250-17. 10.1128/AAC.00250-1728416552PMC5487610

Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 2012;56:2559-64. 10.1128/AAC.06187-1122354310PMC3346605

Butler MS, Paterson DL. Antibiotics in the clinical pipeline in October 2019. J Antibiot 2020;73:329-64. 10.1038/s41429-020-0291-832152527PMC7223789

W, Chan J. Eravacycline injection (Xerava). Inter Med Alert 2018;40.

Scott LJ. Eravacycline: a review in complicated intra-abdominal infections. Drugs 2019;79:315-24. 10.1007/s40265-019-01067-330783960PMC6505493

Sutcliffe JA, O'brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 2013;57:5548-58. 10.1128/AAC.01288-1323979750PMC3811277

McCarthy MW. Clinical pharmacokinetics and pharmacodynamics of eravacycline. Clin Pharmacokinet 2019;58:1149-53. 10.1007/s40262-019-00767-z31049869

Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2213 Gram- negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis 2018;91:55-62. 10.1016/j.diagmicrobio.2017.12.01329338931

Rodvold KA. Eravacycline. In: Grayson ML, Cosgrove S, Crowe S, Hope W, McCarthy J, Mills J, et al, editors. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 7th ed. Boca Raton: CRC Press; 2017. P.1273-89.

Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents 2018;51:62-4. 10.1016/j.ijantimicag.2017.06.02228705668

Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013;41:110-6. 10.1016/j.ijantimicag.2012.09.00523127485

Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-80. 10.1093/jac/dki24816040625

Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006;19:155-61. 10.1080/08998280.2006.1192815416609746PMC1426172

Thaker M, Spanogiannopoulos P, Wright GD. The tetracycline resistome. Cell Mol Life Sci 2010;67:419-31. 10.1007/s00018-009-0172-619862477

Clark RB, Hunt DK, He M, Achorn C, Chen CL, Deng Y, et al. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. J Med Chem 2012;55:606-22. 10.1021/jm201467r22148555

Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 2014;58:2113-8. 10.1128/AAC.02036-1324468780PMC4023791

Petraitis V, Petraitiene R, Maung BBW, Khan F, Alisauskaite I, Olesky M, et al. Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits. Antimicrob Agents Chemother 2018;62:e00275-18. 10.1128/AAC.00275-1829941646PMC6125520

Newman JV, Zhou J, Izmailyan S, Tsai L. Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother 2019;63:e01810-18. 10.1128/AAC.01810-1830559132PMC6395926

Medicines Agency. Xerava (Eravacycline): summary of product characteristics. 2018.

Eckburg PB, Skarinsky D, Das A, Ellis-Grosse EJ. Phenotypic antibiotic resistance in ZEUS: a multi-center, randomized, double-blind phase 2/3 study of ZTI-01 vs. piperacillin-tazobactam (P-T) in the treatment of patients with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP). Open Forum Infect Dis 2017;4:S522. 10.1093/ofid/ofx163.1360

Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10. 10.1086/5162849455502

Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis 2019;69:S565-75. 10.1093/cid/ciz83031724043PMC6853760

Thabit AK, Monogue ML, Nicolau DP. Eravacycline pharmacokinetics and challenges in defining humanized exposure in vivo. Antimicrob Agents Chemother 2016;60:5072-5. 10.1128/AAC.00240-1627353264PMC4958217

Bassetti M, Corey R, Doi Y, Morrissey I, Grossman T, Olesky M, et al. In vitro global surveillance of eravacycline and comparators against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, including multidrug- resistant (MDR) isolates, over a 3-year period (2013-2015). Open Forum Infect Dis 2016;3:1825. 10.1093/ofid/ofw172.1373

Morrissey I, Olesky M, Hawser S, Lob SH, Karlowsky JA, Corey GR, et al. In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother 2020;64:e01699-19. 10.1128/AAC.01699-1931843999PMC7038303

Bassetti M, Melchio M, Giacobbe DR. Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. Expert Rev Anti Infect Ther 2022;20:649-56. 10.1080/14787210.2021.202009834913817

Chahine EB, Dougherty JA, Thornby KA, Guirguis EH. Antibiotic approvals in the last decade: are we keeping up with resistance? Ann Pharmacother 2022;56:441-62. 10.1177/1060028021103139034259076

Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 2017;152:224-32. 10.1001/jamasurg.2016.423727851857

Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 2014;58:1847-54. 10.1128/AAC.01614-1324342651PMC4023720

Nguyen F, Starosta AL, Arenz S, Sohmen D, Dönhöfer A, Wilson DN. Tetracycline antibiotics and resistance mechanisms. Biol Chem 2014;395:559-75. 10.1515/hsz-2013-029224497223

Wen Z, Shang Y, Xu G, Pu Z, Lin Z, Bai B, et al. Mechanism of eravacycline resistance in clinical Enterococcus faecalis isolates from China. Front Microbiol 2020;11:916. 10.3389/fmicb.2020.0091632523563PMC7261854

Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2015;59:1802-5. 10.1128/AAC.04809-1425534744PMC4325809

Clark JA, Kulengowski B, Burgess DS. In vitro activity of eravacycline compared with tigecycline against carbapenem- resistant Enterobacteriaceae. Int J Antimicrob Agents 2020;56:106178. 10.1016/j.ijantimicag.2020.10617832980393

Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother 2018;62:e01174-18. 10.1128/AAC.01174-1830150464PMC6201080

Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis 2019;38:1787-94. 10.1007/s10096-019-03590-331175478

Bassères E, Begum K, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Miranda J, et al. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother 2020;75:2879-84. 10.1093/jac/dkaa28932719870PMC7678891

Rusu A, Buta EL. The development of third-generation tetracycline antibiotics and new perspectives. Pharmaceutics 2021;13:2085. 10.3390/pharmaceutics1312208534959366PMC8707899

Information

Publisher :The Korean Society for Microbiology and The Korean Society of Virology
Publisher(Ko) :대한미생물학회‧대한바이러스학회
Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
Volume : 54
No :1
Pages :1-11
Received Date : 2024-01-02
Revised Date : 2024-03-21
Accepted Date : 2024-03-27
DOI :https://doi.org/10.4167/jbv.2024.54.1.001

JOURNAL OF BACTERIOLOGY AND VIROLOGY ISSN:1598-2467(Print) 2093-0429(Online)

All Issue